Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions
- 1 October 2012
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 12 (5) , 661-671
Abstract
Background: Multiple reforms have been introduced in the Republic of Srpska to enhance prescribing efficiency. Objectives: First, assess their influence on utilization and expenditure on proton-pump inhibitors, statins and renin-angiotensin inhibitor drugs. Second, assess whether the Republic can obtain low prices for generics. Third, suggest additional reforms that could be introduced. Methods: Observational study of all ambulatory care patients between 2003 and 2010. Defined daily doses (DDDs) and DDDs per 1000 inhabitants per day used for measuring changes in utilization. Reimbursed expenditure used as health insurance perspective. Results: Increasing utilization in all three classes. Utilization of angiotensin-receptor blockers principally limited by prescribing restrictions. Reimbursed expenditure/DDD in all three classes decreased by up to 82% in 2010 versus 2004, appreciably improving prescribing efficiency for the statins. Increased utilization of esomeprazole at higher reimbursed expenditure/DDD, and similarly angiotensin-converting enzyme-inhibitor combinations at higher expenditure versus single drugs, limited the ability to fully capitalise on these reductions. Conclusion: Multiple measures helped lower expenditure/DDD, providing hope to countries with small populations. Additional measures are planned to further improve prescribing efficiency in the Republic of Srpska.Keywords
This publication has 34 references indexed in Scilit:
- European payer initiatives to reduce prescribing costs through use of genericsGenerics and Biosimilars Initiative Journal, 2012
- Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency?Reviews in Health Care, 2011
- Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the futureExpert Review of Pharmacoeconomics & Outcomes Research, 2011
- Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costsExpert Review of Pharmacoeconomics & Outcomes Research, 2011
- Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implicationsExpert Review of Pharmacoeconomics & Outcomes Research, 2010
- Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Pharmaceuticals, 2010
- Ongoing pharmaceutical reforms in FranceApplied Health Economics and Health Policy, 2010
- Enhancing the rational use of new medicines across European health care systemsEuropean Journal of Clinical Pharmacology, 2008
- Insight into recent reforms and initiatives in Austria: implications for key stakeholdersExpert Review of Pharmacoeconomics & Outcomes Research, 2008
- Recent National and Regional Drug Reforms in SwedenPharmacoEconomics, 2008